文献速递浆细胞疾病

风湿性疾病影响MGUS进展为显性多发性骨髓瘤的风险

Rheumatologic diseases impact the risk of progression of MGUS to overt multiple myeloma.
PubMed 文献 · Blood Adv · 2021-01-01

该研究纳入2000年1月至2016年8月诊断的2935例MGUS患者,其中255例(9%)合并风湿性疾病。

要点

  • MGUS合并非抗体介导的风湿性疾病时,进展为多发性骨髓瘤的风险翻倍。
  • 非抗体介导风湿性疾病组5年进展风险为10%,无风湿合并症组为4%。
  • 抗体介导的风湿性疾病组5年进展风险为2%。

核心结论

  • 慢性炎症性疾病影响MGUS进展为显性多发性骨髓瘤的风险,非抗体介导的风湿性疾病患者转化风险翻倍。

研究设计与样本

  • 研究纳入2000年1月至2016年8月诊断的2935例MGUS患者,其中255例(9%)合并风湿性疾病。
  • 风湿性疾病分为抗体介导和非抗体介导两组,非抗体介导组包括风湿性多肌痛、大血管巨细胞动脉炎、脊柱关节炎和痛风。
  • 进展定义为分类变量(是/否)或连续时间依赖变量(进展时间)。

主要发现

  • 5年进展风险:无风湿合并症者4%,非抗体介导风湿性疾病者10%,抗体介导风湿性疾病者2%。

临床怎么用

  • 对于MGUS患者,应评估是否合并风湿性疾病,尤其是非抗体介导的风湿性疾病,以识别进展高风险人群。
  • 未来研究可探讨是否将风湿性疾病等合并症纳入现有MGUS预后评分体系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Monoclonal gammopathy of undetermined significance (MGUS), a premalignant condition, is associated with various chronic inflammatory rheumatic diseases (RDs) and is frequently observed as an incidental finding during routine work-up. The association of MGUS and chronic RDs is well established, but the impact of RDs on the risk of transformation into overt multiple myeloma (MM) has not been evaluated so far. MGUS patients diagnosed between January 2000 and August 2016 were identified and screened for concomitant RDs. RDs were grouped into antibody (Ab)-mediated RDs and non-Ab-mediated RDs (polymyalgia rheumatica, large-vessel giant cell arteritis, spondyloarthritis, and gout). Progression to MM was defined as a categorical (yes/no) or continuous time-dependent (time to progression) variable. Of 2935 MGUS patients, 255 (9%) had a concomitant RD. MGUS patients diagnosed with non-Ab-mediated RDs had a doubled risk of progression compared with those without a concomitant RD (hazard ratio, 2.1; 95% CI, 1.1-3.9; P = .02). These data translate into a 5-year risk of progression of 4% in MGUS patients without rheumatologic comorbidity, 10% in those with concomitant non-Ab-mediated RDS, and 2% in those with Ab-mediated RDs. By using the complex risk stratification model that includes myeloma protein (M-protein) concentration, immunoglobulin type, and level of free light chain ratio as variables, patients with non-Ab-mediated RDs (n = 57) had the highest risk for progression (hazard ratio, 6.8; 95% CI, 1.5-30.7; P = .01) compared with patients with Ab-mediated RDs (n = 77). Chronic inflammatory diseases have an impact on the risk of MGUS progressing into overt MM, with a doubled risk of transformation observed in patients with non-Ab-mediated RDs. Future research can elucidate whether comorbidities such as RDs should be included in currently applied prognostic MGUS scores.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Steiner N, Göbel G, Michaeler D, et al. Rheumatologic diseases impact the risk of progression of MGUS to overt multiple myeloma. Blood Adv. 2021. PMID: 33749761. doi:10.1182/bloodadvances.2020003193

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。